Sector | Healthcare | Compare with Sector peers |
Industry | Pharmaceuticals & Drugs | Compare with Industry peers |
Website | http://www.panaceabiotec.com | |
Market Cap | 854.45 Cr. | |
Enterprise Value(EV) | 737.96 Cr. | 2023-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | -1.99 | Trailing Twelve Months Ending 2023-12 |
Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2023-12 |
Industry PE | 42.37 | Trailing Twelve Months Ending 2023-12 |
Book Value / Share | 137.92 | Trailing Twelve Months Ending 2023-12 |
Price to Book Value | 1.01 | Calculated using Price: 139.50 |
Dividend Yield | 0.00 | Period Ending 2023-03 |
No. of Shares Subscribed | 6.13 Cr. | 61,250,746 Shares |
FaceValue | 1 | |
About Panacea Biotec Ltd. | ||
The company has product portfolio that's caters therapeutics areas like pain management, diabetes and cardiovascular management, renal disease management, osteoporosis management, anti-tubercular, gastro-intestinal. Business Areas of the Company :- (1) Research and Development (R&D) – Under this the company primarily focuses on New Chemical Entities (NCE), New Biological Entities (NBE) and Novel Drug Delivery System (NDDS). (2) Vaccines- Under this the company has product portfolio of oral polio vaccines and Hepatitis-B vaccines. (3) Formulations- It has created flagship brands like Willgo for pain management, Glizid & Glizid-M for diabetes; Panimun Bioral and Mycept for kidney transplant. |
1 Day |
|
-0.43% |
1 Week |
|
-4.55% |
1 Month |
|
+3.41% |
3 Month |
|
-15.43% |
6 Month |
|
-7.25% |
1 Year |
|
+13.83% |
2 Year |
|
-11.60% |
5 Year |
|
-29.10% |
10 Year |
|
-12.68% |
9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | -253.03 | 0 | -34.38 | -22.94 | 11.39 | -75.26 | 0 | 332.85 | -3.92 | |
Return on Capital Employed (%) | 0.45 | 9.93 | 2.76 | 2.63 | 13.44 | -0.38 | 5.36 | 217.12 | 1.94 | |
Return on Assets (%) | -4.87 | -1.01 | -2.97 | -4.53 | 2.55 | -13.36 | -10.69 | 74.05 | -2.24 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
Shh. Funds | 471 | 449 | 356 | 309 | 350 | 199 | -229 | 877 | 844 | 847 | |
Non Curr. Liab. | 918 | 1,100 | 719 | 591 | 70 | 741 | 960 | 85 | 99 | 97 | |
Curr. Liab. | 706 | 475 | 689 | 696 | 938 | 622 | 447 | 774 | 330 | 332 | |
Minority Int. | 3 | 1 | 11 | -3 | -3 | -3 | -3 | -3 | -3 | -4 | |
Equity & Liab. | 2,099 | 2,025 | 1,774 | 1,592 | 1,356 | 1,559 | 1,177 | 1,735 | 1,271 | 1,272 | |
Non Curr. Assets | 1,573 | 1,475 | 1,071 | 1,028 | 848 | 875 | 666 | 745 | 703 | 737 | |
Curr. Assets | 526 | 549 | 703 | 565 | 508 | 683 | 474 | 951 | 562 | 535 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 2,099 | 2,025 | 1,774 | 1,592 | 1,356 | 1,559 | 1,177 | 1,735 | 1,271 | 1,272 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
Net Sales | 687 | 653 | 544 | 593 | 457 | 544 | 625 | 661 | 460 | 552 | |
Other Income | 28 | 20 | 47 | 8 | 5 | 30 | 10 | 11 | 52 | 30 | |
Total Income | 716 | 673 | 591 | 601 | 462 | 574 | 635 | 672 | 512 | 582 | |
Total Expenditure | -643 | -541 | -497 | -508 | -590 | -519 | -548 | -674 | -558 | -571 | |
PBIDT | 72 | 132 | 94 | 93 | -128 | 56 | 87 | -2 | -46 | 10 | |
Interest | -105 | -127 | -101 | -101 | -105 | -174 | -185 | -181 | -4 | -4 | |
Depreciation | -67 | -73 | -68 | -59 | -55 | -44 | -46 | -44 | -39 | -37 | |
Taxation | -3 | -2 | 11 | -10 | -9 | -17 | -2 | -371 | -47 | -34 | |
Exceptional Items | 50 | 8 | 334 | -15 | 1,676 | 103 | 53 | ||||
PAT | -102 | -21 | -56 | -76 | 38 | -195 | -146 | 1,078 | -34 | -12 | |
Minority Interest | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 1 | ||
Share Associate | -6 | 0 | 0 | 0 | 0 | 0 | |||||
Other Related Items | |||||||||||
Consolidated Net Profit | -107 | -18 | -54 | -74 | 38 | -194 | -148 | 1,078 | -33 | -12 | |
Adjusted EPS | -17 | -3 | -9 | -12 | 6 | -32 | -24 | 176 | -5 | -2 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | 54 | 37 | 91 | 131 | 118 | 105 | -30 | 107 | -108 | -422 | |
Cash Fr. Inv. | -38 | -37 | 16 | -26 | 55 | -5 | -35 | -48 | 1,283 | 430 | |
Cash Fr. Finan. | -30 | -1 | -117 | -107 | -164 | -101 | 91 | -47 | -1,176 | -18 | |
Net Change | -14 | -1 | -10 | -2 | 9 | -2 | 26 | 12 | -2 | -10 | |
Cash & Cash Eqvt | 21 | 20 | 10 | 7 | 16 | 14 | 40 | 52 | 50 | 40 |
Thu, 02 May 2024
Intimation Regarding Appointment Of Senior Management Personnel In The Company'S Material Subsidiary Viz. Panacea Biotec Pharma Limited We would like to inform you that Mr. Rishi Prakash Vice President - Business Development has been appointed as Senior Management Personnel of Panacea Biotec Pharma Ltd w.e.f. May 01 2024.The disclosure pursuant to SEBI Circular dated July 13 2023 is attached herewith. |
|||||||||||||||||||||
Tue, 30 Apr 2024
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A Format of Initial Disclosure to be made by an entity identified as a Large Corporate.
We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No Name of the Company Secretary: Vinod Goel Designation: Group CFO and Head Legal and Company Secretary EmailId: vinodgoel@panaceabiotec.com Name of the Chief Financial Officer: Devender Gupta Designation: Chief Financial Officer and Head IT EmailId: devendergupta@panaceabiotec.com Date: 30/04/2024 Note: In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. |
|||||||||||||||||||||
Mon, 29 Apr 2024
Intimation Regarding Resignation Of Senior Management Personnel Of The Company'S Material Subsidiary Viz. Panacea Biotec Pharma Limited ('PBPL') We would like to inform you that Mr. Sanjay Kumar Sr. General Manager - Quality (Pharma & Oncology) of the Companys material subsidiary Panacea Biotec Pharma Ltd. has tendered his resignation. In this regard a copy of the resignation letter is attached herewith as Annexure -A |
Thu, 02 May 2024 |
Opening at High |
Closing Below Previous Low |
Closing Below Previous Low for 3 days |
Making Lower Lows for 3 days |
Closing Below Previous Low for 2 Days |